Attached files

file filename
EX-10.4 - EXHIBIT 10.4 - GlyEco, Inc.s105835_ex10-4.htm
EX-10.3 - EXHIBIT 10.3 - GlyEco, Inc.s105835_ex10-3.htm
EX-10.2 - EXHIBIT 10.2 - GlyEco, Inc.s105835_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - GlyEco, Inc.s105835_ex10-1.htm
8-K - 8-K - GlyEco, Inc.s105835_8k.htm

 

Exhibit 99.1

 

On Thursday, April 6, 2017 at 5:13 PM ET

 

 

GlyEco Reports Fourth Quarter 2016 Results

 

Quarter and Full Year Positive Gross Margin

Adjusted Revenues Increased 8% for the Quarter

 

ROCK HILL, SC / ACCESSWIRE / April 6, 2017 / GlyEco, Inc. ("GlyEco" or the "Company") (OTC PINK: GLYE), a leading specialty chemical company, announced today the following financial results for the quarter and year ended December 31, 2016:

 

   Quarter ended
December 31,
 
   2016   2015 
Sales, net  $1,445,346   $1,838,176 
Gross profit (loss)  $130,793   $(358,265)
Total operating expenses  $775,702   $9,258,092 
Loss from operations  $(644,909)  $(9,616,357)
Net income (loss)  $283,417   $(9,662,014)
Adjusted EBITDA  $(423,243)  $(9,341,438)

 

   Year ended December 31, 
   2016   2015 
Sales, net  $5,591,087   $7,364,452 
Gross profit (loss)  $308,033   $(803,389)
Total operating expenses  $3,492,475   $11,477,791 
Loss from operations  $(3,184,442)  $(12,281,180)
Net loss  $(2,264,560)  $(12,452,260)
Adjusted EBITDA  $(1,836,531)  $(10,600,569)

 

"The Company's financial performance for the quarter ended December 31, 2016, was, by several financial measures, one of our best quarters of 2016 and a significant improvement over the fourth quarter of 2015," said Ian Rhodes, GlyEco's President and Chief Executive Officer. "The WEBA, RS&T and Dow asset acquisitions in December 2016 capped off a year of meaningful progress and have given us significant momentum for 2017 and beyond."

 

Fourth Quarter of 2016 Highlights

 

·Positive gross margin of $131,000 for the three months ended December 31, 2016, compared to a negative gross margin of $358,000 for the three months ended December 31, 2015.
·Increased Revenues (excluding revenues related to our Elizabeth, NJ facility) by $104,000 or 8%, from $1.26 million for the three months ended December 31, 2015, to $1.36 million for the three months ended December 31, 2016.

 

 

 

 

·Operating loss of $645,000 for the three months ended December 31, 2016, compared to $9.6 million for the three months ended December 31, 2015. 2015 included an impairment loss, primarily related to exiting the New Jersey facility, of $8.6 million.
·Adjusted EBITDA of negative $423,000 for the three months ended December 31, 2016, compared to negative $9.3 million for the three months ended December 31, 2015. 2015 included an impairment loss, primarily related to exiting the New Jersey facility, of $8.6 million.
·Completed the previously announced acquisitions of WEBA Technology Corp, Recovery Solutions & Technologies Inc. and certain assets from The Dow Chemical Company.
·Average monthly distillation production was 67,000 gallons for the three months ended December 31, 2016, the highest quarterly average for 2016 and a significant increase from an average monthly distillation production of 44,000 gallons for the three months ended March 31, 2016.
·Cash of $1.4 million at December 31, 2016.

 

Fourth Quarter of 2016 Financial Review

 

The Company's sales were $1.45 million for the quarter ended December 31, 2016, compared to $1.84 million for the quarter ended December 31, 2015, a decrease of $393,000, or 21%. The decrease in sales was due to the impact of the closure of our former New Jersey processing center in 2015, partially offset by the addition of new customers.

 

The Company realized a gross profit of $131,000 for the quarter ended December 31, 2016, compared to a gross loss of $358,000 for the quarter ended December 31, 2015, as cost of goods sold decreased primarily as a result of the closure of the New Jersey processing facility in December 2015 and year over year improvements in operations; in particular, production improvements.

 

The Company reported an operating loss of $645,000 for the quarter ended December 31, 2016, compared to a $9.6 million operating loss for the quarter ended December 31, 2015. 2015 included an impairment loss, primarily related to exiting the New Jersey facility, of $8.6 million. Excluding the $8.6 million impairment loss, the operating loss for the quarter decreased approximately $338,000 as the improvement in gross margin was partially offset by increased operating expenses related to salaries and wages and general and administrative expenses as the Company built out its in house technical resources and ramped up its sales efforts.

 

The Company reported net income of $283,000 for the quarter ended December 31, 2016, compared to a net loss of $9.7 million for the quarter ended December 31, 2015. 2016 includes an income tax benefit of $1.0 million related to the WEBA acquisition. 2015 included an impairment loss, primarily related to exiting the New Jersey facility, of $8.6 million.

 

The Company reported adjusted EBITDA of negative $423,000 for the three months ended December 31, 2016, compared to negative $9.3 million for the three months ended December 31, 2015. 2015 included an impairment loss, primarily related to exiting the New Jersey facility, of $8.6 million.

 

Full Year of 2016 Financial Review

 

The Company's sales were $5.59 million for 2016, compared to $7.36 million for 2015, a decrease of $1.77 million, or 24%. The decrease in sales was due to the impact of the closure of our former Elizabeth, New Jersey processing center in 2015, partially offset by the addition of new customers.

 

The Company realized a gross profit of $308,000 for 2016, compared to a gross loss of $803,000 for 2015, as cost of goods sold decreased primarily as a result of the closure of our Elizabeth, New Jersey processing facility in December 2015 and year over year improvements in operations, which are primarily attributable to significant production improvements.

 

 

 

 

The Company reported an operating loss of $3.18 million for 2016, compared to a $12.28 million operating loss for 2015. 2015 included an impairment loss, primarily related to exiting the New Jersey, of $8.6 million. Excluding the $8.6 million impairment loss, the operating loss for the year decreased approximately $463,000 as the improvement in gross margin was partially offset by increased operating expenses related to salaries and wages and general and administrative expenses as the Company built out its in house technical resources and ramped up its sales efforts and incurred approximately $500,000 of costs in the first half of 2016 related to the wind down of the NJ facility.

 

The Company reported a net loss of $2.26 million for 2016, compared to $12.45 million for 2015. 2016 includes an income tax benefit of $1.0 million related to the WEBA acquisition. 2015 included an impairment loss, primarily related to exiting the New Jersey facility, of $8.6 million.

 

The Company reported adjusted EBITDA of negative $1.84 million for 2016, compared to negative $10.6 million for 2015. 2015 included an impairment loss, primarily related to exiting the New Jersey facility, of $8.6 million.

 

Business Update

 

We made good progress in the fourth quarter of 2016 in several areas; most notably sustaining higher levels of production across our facilities. These production gains had a direct and visible impact on our fourth quarter and full year 2016 results. These gains were the result of thoughtful capital expenditures and the hard work of our entire operations team.

 

We also made significant progress in advancing our quality assurance program with a collaborative effort between our operations team and our technical resources personnel. Producing high quality products - every batch and every day - is key to the success of our business, and having a quality assurance program that supports us in producing high quality products is important. We are very proud of the products we produce and the people that make them.

 

We launched an aggressive sales effort in the fourth quarter of 2016. This would not have been possible without the great people of our company, including our customer service team, that provide our customers with best-in- class customer service each and every day. Our sales efforts are just getting started, but we are excited about the opportunities for growth.

 

Finally, we closed 2016 with several transactions - the acquisitions of WEBA, RS&T and certain Dow assets - that we expect will have a significant positive impact in 2017 and beyond.

 

About GlyEco, Inc.

 

GlyEco is a leading specialty chemical company, leveraging technology and innovation to focus on vertically integrated, eco-friendly manufacturing, customer service and distribution solutions. Our eight facilities, including the recently acquired 14-20 million gallons per year ASTM E1177 EG-1 glycol re-distillation plant in West Virginia, deliver superior quality glycol products that meet or exceed ASTM quality standards, including a wide spectrum of ready to use antifreezes and additive packages for antifreeze/coolant, gas patch coolants and heat transfer fluid industries throughout North America. Our team's extensive experience in the chemical field, including direct experience with reclamation of all types of glycols, gives us the ability to process a wide range of feedstock streams, formulate and produce unique products and maintain an outstanding reputation in our markets.

 

For further information, please visit: http://www.glyeco.com.

 

 

 

 

Safe Harbor Statement

 

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the words "believe," "anticipate," "expect," "intend," "estimate," and similar expressions. All statements in this document regarding the future outlook related to GlyEco, Inc. are forward-looking statements. Such statements are based on the current expectations, beliefs, estimates and projections of management and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements including the risk that the future data will not be as favorable as the initial results. Additional uncertainties and risks are described in our most recent Annual Report on Form 10-K. For a more detailed discussion of factors that affect GlyEco's operations, please refer our filings with the Securities and Exchange Commission ("SEC"). Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to us on the date hereof, and GlyEco undertakes no obligation to update this forward-looking information.

 

Contact:

 

GlyEco, Inc.

Ian Rhodes

President and Chief Executive Officer

irhodes@glyeco.com

866-960-1539

 

 

 

 

GLYECO, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

December 31, 2016 and 2015

 

   December 31,   December 31, 
   2016   2015 
ASSETS          
Current Assets          
Cash  $1,413,999   $1,276,687 
Cash – restricted   76,552    - 
Accounts receivable, net   1,096,713    807,906 
Prepaid expenses and other current assets   340,899    95,775 
Inventories   644,522    380,789 
Total current assets   3,572,685    2,561,157 
Property, plant and equipment, net   3,657,839    1,279,057 
Other Assets          
Deposits   387,035    26,688 
Goodwill   3,693,083    835,295 
Other intangibles, net   2,794,204    169,533 
Total other assets, net   6,874,322    1,031,516 
Total assets  $14,104,846   $4,871,730 
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current Liabilities          
Accounts payable and accrued expenses  $961,010   $1,522,037 
Due to related parties   6,191    34,405 
Contingent acquisition consideration   1,821,575    - 
Notes payable – current portion, net of debt discount   2,541,178    117,972 
Capital lease obligations – current portion   6,838    9,752 
Total current liabilities   5,336,792    1,684,166 
Non-Current Liabilities          
Notes payable – non-current portion   2,963,640    - 
Capital lease obligations – non-current portion   3,371    10,211 
Total non-current liabilities   2,967,011    10,211 
Total liabilities   8,303,803    1,694,377 
Commitments and Contingencies          
Stockholders' Equity          
Preferred stock: 40,000,000 shares authorized; $0.0001 par value; no shares issued and outstanding as of December 31, 2016 and 2015   -    - 
Common Stock: 300,000,000 shares authorized; $0.0001 par value; 126,156,189 and 72,472,412 shares issued and outstanding as of December 31, 2016 and 2015, respectively   12,616    7,248 
Additional paid-in capital   42,603,490    37,720,608 
Accumulated deficit   (36,815,063)   (34,550,503)
Total stockholders' equity   5,801,043    3,177,353 
Total liabilities and stockholders' equity  $14,104,846   $4,871,730 

 

 

 

 

GLYECO, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

For the years ended December 31, 2016 and 2015

 

   Years Ended December 31, 
   2016   2015 
Net sales  $5,591,087   $7,364,452 
Cost of goods sold   5,283,054    8,167,841 
Gross profit (loss)   308,033    (803,389)
Operating expenses:          
Consulting fees   129,752    324,947 
Share-based compensation   1,064,086    887,173 
Salaries and wages   1,094,465    549,578 
Legal and professional   274,824    300,350 
General and administrative   929,348    781,982 
Impairment loss   -    8,633,761 
Total operating expenses   3,492,475    11,477,791 
Loss from operations   (3,184,442)   (12,281,180)
Other (income) and expense:          
Interest income   (372)   (231)
Interest expense   25,876    160,937 
Loss on sale of equipment, net   89,666    - 
Gain on settlement of note payable   (15,000)   - 
Total other expense, net   100,170    160,706 
Loss before provision for income taxes   (3,284,612)   (12,441,886)
(Benefit) provision for income taxes   (1,020,052)   10,374 
Net loss  $(2,264,560)  $(12,452,260)
Basic and diluted net loss per share  $(0.02)  $(0.18)
Weighted average common shares outstanding (basic and diluted)   109,553,834    69,113,112 

 

 

 

 

GLYECO, INC. AND SUBSIDIARIES

Adjusted Earnings before Interest, Taxes, Depreciation and Amortization

(non-GAAP)

For the years ended December 31, 2016 and 2015

 

   As Reported 
   Years Ended December 31, 
   2016   2015 
Net loss  $(2,264,560)  $(12,452,260)
Interest expense, net   25,504    160,706 
Income tax (benefit) expense   (1,020,052)   10,374 
Depreciation and amortization   358,491    793,438 
Share-based compensation   1,064,086    887,173 
Adjusted EBITDA  $(1,836,531)  $(10,600,569)

 

Presented above is the non-GAAP financial measure representing earnings before interest, taxes, depreciation, amortization and stock compensation (which we refer to as "Adjusted EBITDA") and the reconciliations of Adjusted EBITDA to net loss. Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for, net income (loss) and cash flows from operations calculated in accordance with GAAP.

 

Adjusted EBITDA is used by our management as an additional measure of our Company's performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our Company's financial results that may not be shown solely by period-to-period comparisons of net income (loss) and cash flows from operations. In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to many of our employees in order to evaluate our Company's performance. Further, we believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results and helps investors make comparisons between our company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net income (loss), as well as trends in those items.

 

SOURCE: GlyEco, Inc.